Method of treating a disorder associated with mtp 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
WO2010148179 A1 2010-12-23 [WO2010148179]WO2010148179 A8 2011-04-21 [WO2010148179] / 2010-12-232011-04-21
申请号/申请日
2010WO-US38965 / 2010-06-17
发明人
KON HARUTOSHI;MASUDA YOSHIRO;WATANABE HIROMITSU;FRIEND II JOHN EDWIN;
申请人
JAPAN TOBACCO;
主分类号
IPC分类号
A01N-043/40A61K-031/445
摘要
(WO2010148179) Provided is a method of treating or preventing a disorder in a subject comprising administering twice per day a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate, or hydrate thereof, to a subject that has or is at risk of having a disorder selected from the group consisting of hyperlipidemia, arteriosclerosis, coronary artery diseases, metabolic syndrome, obesity, diabetes, prediabetes, and hypertension, whereupon the disorder is treated or prevented in the subject.  The method optionally comprises administering a therapeutically effective amount of the compound of formula (I), or a pharmaceutically acceptable salt, solvate, or hydrate thereof, to the subject, in which the therapeutically effective amount is increased once or twice during the course of administration.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2009US-61268925 2009-06-18
主权利要求
(WO2010148179) 1. CLAIM(S): 1. A method of treating or preventing a disorder in a subject comprising administering twice per day a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate, or hydrate thereof, to a subject that has or is at risk of having a disorder selected from the group consisting of hyperlipidemia, arteriosclerosis, coronary artery diseases, obesity, diabetes and hypertension, whereupon the disorder is treated or prevented in the subject. 2. The method of claim 1, wherein the therapeutically effective amount is about 0.5 mg to 10 mg. 3. The method of claim 1, wherein the therapeutically effective amount is about 1 mg. 4. The method of claim 1, wherein the therapeutically effective amount is about 1.5 mg. 5. The method of claim 1, wherein the therapeutically effective amount is about 2 mg. 6. The method of claim 1, wherein the therapeutically effective amount is about 2.5 mg. 7. The method of claim 1, wherein the therapeutically effective amount is about 3 mg. 8. The method of claim 1 , wherein the therapeutically effective amount is about 3.5 mg. 9. The method of claim 1, wherein the therapeutically effective amount is about 4 mg. 10. The method of claim 1, wherein the therapeutically effective amount is about 4.5 mg. 1 1. The method of claim 1, wherein the therapeutically effective amount is about 5 mg. 12. The method of claim 1, wherein the method comprises administering twice per day a therapeutically effective amount of the compound of formula (I), or a pharmaceutically acceptable salt, solvate, or hydrate thereof, to the subject, and the therapeutically effective amount is increased once during the course of the administration of the compound of formula (I), or a pharmaceutically acceptable salt, solvate, or hydrate thereof. 13. The method of claim 12, wherein the method comprises (a) administering twice per day a first therapeutically effective amount of the compound of formula (I), or a pharmaceutically acceptable salt, solvate, or hydrate thereof, to the subject for a first time period, and (b) administering twice per day a second therapeutically effective amount of the compound of formula (I), or a pharmaceutically acceptable salt, solvate, or hydrate thereof, to the subject for a second time period after the first time period, wherein the second therapeutically effective amount is greater than the first therapeutically effective amount. 14. The method of claim 13, wherein the first time period is about 1 to 5 weeks. 15. The method of claim 13, wherein the first time period is about 2 to 4 weeks. 16. The method of claim 13, wherein the first time period is about 2 weeks. 17. The method of any one of claims 13-16, wherein the first therapeutically effective amount is about 0.5 mg. 18. The method of any one of claims 13-16, wherein the first therapeutically effective amount is about 1 mg. 19. The method of any one of claims 13-16, wherein the first therapeutically effective amount is about 1.5 mg. 20. The method of any one of claims 13-16, wherein the first therapeutically effective amount is about 2 mg. 21. The method of any one of claims 13-16, wherein the first therapeutically effective amount is about 2.5 mg. 22. The method of any one of claims 13-16, wherein the first therapeutically effective amount is about 3 mg. 23. The method of any one of claims 13-16, wherein the first therapeutically effective amount is about 3.5 mg. 24. The method of any one of claims 13-16, wherein the first therapeutically effective amount is about 4 mg. 25. The method of any one of claims 13-16, wherein the first therapeutically effective amount is about 4.5 mg. 26. The method of any one of claims 13-16, wherein the first therapeutically effective amount is about 5 mg. 27. The method of any one of claims 13-26, wherein the second therapeutically effective amount is at least 25% greater than the first therapeutically effective amount. 28. The method of any one of claims 13-26, wherein the second therapeutically effective amount is at least 50% greater than the first therapeutically effective amount. 29. The method of any one of claims 13-26, wherein the second therapeutically effective amount is at least 75% greater than the first therapeutically effective amount. 30. The method of any one of claims 13-26, wherein the second therapeutically effective amount is at least 100% greater than the first therapeutically effective amount. 31. The method of claim I5wherein the method comprises administering twice per day a therapeutically effective amount of the compound of formula (I), or a pharmaceutically acceptable salt, solvate, or hydrate thereof, to the subject, and the therapeutically effective amount is increased twice during the course of the administration of the compound of formula (I), or a pharmaceutically acceptable salt, solvate, or hydrate thereof. 32. The method of claim 31, wherein the method comprises (a) administering twice per day a first therapeutically effective amount of the compound of formula (I), or a pharmaceutically acceptable salt, solvate, or hydrate thereof, to the subject for a first time period, (b) administering twice per day a second therapeutically effective amount of the compound of formula (I), or a pharmaceutically acceptable salt, solvate, or hydrate thereof, to the subject for a second time period after the first time period, and (c) administering twice per day a third therapeutically effective amount of the compound of formula (I), or a pharmaceutically acceptable salt, solvate, or hydrate thereof, to the subject for a third time period after the second time period, wherein the second therapeutically effective amount is greater than the first therapeutically effective amount, and the third therapeutically effective amount is greater than the second therapeutically effective amount. 33. The method of claim 32, wherein the first and second time periods are each independently about 1 to 5 weeks. 34. The method of claim 32, wherein the first and second time periods are each independently about 2 to 4 weeks. 35. The method of claim 32, wherein the first and second time periods are about 2 weeks. 36. The method of any one of claims 32-35, wherein the first therapeutically effective amount is about 0.5 mg. 37. The method of any one of claims 32-35, wherein the first therapeutically effective amount is about 1 mg. 38. The method of any one of claims 32-35, wherein the first therapeutically effective amount is about 1.5 mg. 39. The method of any one of claims 32-35, wherein the first therapeutically effective amount is about 2 mg. 40. The method of any one of claims 32-35, wherein the first therapeutically effective amount is about 2.5 mg. 41. The method of any one of claims 32-35, wherein the first therapeutically effective amount is about 3 mg. 42. The method of any one of claims 32-35, wherein the first therapeutically effective amount is about 3.5 mg. 43. The method of any one of claims 32-35, wherein the first therapeutically effective amount is about 4 mg. 44. The method of any one of claims 32-35, wherein the first therapeutically effective amount is about 4.5 mg. 45. The method of any one of claims 32-35, wherein the first therapeutically effective amount is about 5 mg. 46. The method of any one of claims 32-45, wherein the second therapeutically effective amount is at least 25% greater than the first therapeutically effective amount. 47. The method of any one of claims 32-45, wherein the second therapeutically effective amount is at least 50% greater than the first therapeutically effective amount. 48. The method of any one of claims 32-45, wherein the second therapeutically effective amount is at least 75% greater than the first therapeutically effective amount. 49. The method of any one of claims 32-45, wherein the second therapeutically effective amount is at least 100% greater than the first therapeutically effective amount. 50. The method of any one of claims 32-49, wherein the third therapeutically effective amount is at least 25% greater than the second therapeutically effective amount. 51. The method of any one of claims 32-49, wherein the third therapeutically effective amount is at least 50% greater than the second therapeutically effective amount. 52. The method of any one of claims 32-49, wherein the third therapeutically effective amount is at least 75% greater than the second therapeutically effective amount. 53. The method of any one of claims 32-49, wherein the third therapeutically effective amount is at least 100% greater than the second therapeutically effective amount. 54. The method of any one of claims 1-53, wherein the disorder is obesity. 55. The method of any one of claims 1-53, wherein the disorder is diabetes. 56. The method of claim 55, wherein the diabetes is type 2 diabetes. 57. The method of any one of claims 1-56, wherein the compound is administered to the subject when the subject is in the fed state. 58. The method of claim 57, wherein the compound is administered to the subject with food. 59. The method of claim 57, wherein the compound is administered to the subject 1-180 minutes after the subject has begun to consume food. 60. The method of claim 59, wherein the compound is administered to the subject 5-180 minutes after the subject has begun to consume food. 61. The method of claim 59, wherein the compound is administered to the subject 10-180 minutes after the subject has begun to consume food. 62. The method of claim 59, wherein the compound is administered to the subject 20-180 minutes after the subject has begun to consume food. 63. The method of claim 59, wherein the compound is administered to the subject 30-180 minutes after the subject has begun to consume food. 64. The method of any one of claims 59-63, wherein the compound is administered to the subject no more than 120 minutes after the subject has begun to consume food. 65. The method of any one of claims 59-63, wherein the compound is administered to the subject no more than 60 minutes after the subject has begun to consume food. 66. The method of any one of claims 59-63, wherein the compound is administered to the subject no more than 30 minutes after the subject has begun to consume food.
法律状态
(WO2010148179) LEGAL DETAILS FOR WO2010148179  Actual or expected expiration date=2012-12-18    Legal state=DEAD    Status=LAPSED     Event publication date=2010-06-17  Event code=WO/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=WO WOUS2010038965  Application date=2010-06-17  Standardized application number=2010WO-US38965     Event publication date=2010-12-23  Event code=WO/A1  Event type=Examination events  Published application with search report  Publication country=WO  Publication number=WO2010148179  Publication stage Code=A1  Publication date=2010-12-23  Standardized publication number=WO2010148179     Event publication date=2011-04-21  Event code=WO/A8  Event indicator=Pos  Event type=Examination events  International application republished with corrections to front page bibliographic data  Publication country=WO  Publication number=WO2010148179  Publication stage Code=A8  Publication date=2011-04-21  Standardized publication number=WO2010148179     Event publication date=2012-12-18  Event code=WO/EETL  Event type=Event indicating Not In Force  PCT Application validity period expired. LEGAL DETAILS FOR DESIGNATED STATE DE  Actual or expected expiration date=2011-12-19    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=DE     Event publication date=2011-12-19  Event code=WO/NENP  Event type=Event indicating Not In Force  Non-entry into the national phase in: Corresponding cc:  Designated or member state=DE
专利类型码
A1A8
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部